ChiCTR2200055513 版本V1.2 版本创建时间2022/07/29 08:38:24 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200055513 

最近更新日期:

Date of Last Refreshed on:

2022-07-29 08:34:44 

注册时间:

Date of Registration:

2022-01-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

请于伦理委员会批准后才开始征募参试者,并与我们联系上传伦理批件 慢性疲劳综合征药食同源组方的效果观察

Public title:

An observation study of the effect of homologous prescription of medicine and food on chronic fatigue syndrome

注册题目简写:

The effect of homologous prescription of medicine and food in chronic fatigue syndrome

English Acronym:

研究课题的正式科学名称:

慢性疲劳综合征药食同源组方的效果观察

Scientific title:

An observation study of the effect of homologous prescription of medicine and food on chronic fatigue syndrome

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiMCTR2200005527

申请注册联系人:

姚志翠 

研究负责人:

骆彬 

Applicant:

Yao Zhicui 

Study leader:

Luo Bin 

申请注册联系人电话:

Applicant telephone:

+86 15931175599

研究负责人电话:

Study leader's
telephone:

+86 18633889869

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sjzwxyzc@163.com

研究负责人电子邮件:

Study leader's E-mail:

luobinyisheng@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

河北中医学院

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河北省石家庄市东岗路89号

研究负责人通讯地址:

河北省石家庄市东岗路89号

Applicant address:

89 Donggang Road, Shijiazhuang, Hebei

Study leader's address:

89 Donggang Road, Shijiazhuang, Hebei

申请注册联系人邮政编码:

Applicant postcode:

050031

研究负责人邮政编码:

Study leader's postcode:

050031

申请人所在单位:

河北医科大学第一医院

Applicant's institution:

the First Hospital of Hebei Medical University

研究负责人所在单位:

河北医科大学第一医院

Affiliation of the Leader:

the First Hospital of Hebei Medical University

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

河北中医学院

Primary sponsor:

Hebei College of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

河北省石家庄市东岗路89号

Primary sponsor's address:

89 Donggang Road, Shijiazhuang, Hebei

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河北

市(区县):

石家庄

Country:

China

Province:

Hebei

City:

Shijiazhuang

单位(医院):

河北医科大学第一医院

具体地址:

东岗路89号

Institution
hospital:

the First Hospital of Hebei Medical University

Address:

89 Donggang Road

经费或物资来源:

河北省中医药管理局科研计划项目

Source(s) of funding:

Scientific Research Project of Hebei Administration of Traditional Chinese Medicine

研究疾病:

慢性疲劳综合征  

Target disease:

chronic fatigue syndrome

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

依托传统食疗学、中医学等医药保健理论,观察药食同源组方对慢性疲劳综合征患者的干预效果,改善患者生活质量,降低医疗成本。  

Objectives of Study:

Based on traditional dietotherapy, Traditional Chinese medicine and other medical and health care theories, to observe the intervention effect of medicine and food homology prescription on patients with chronic fatigue syndrome, improve the quality of life of patients, reduce medical costs.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1)使用美国疾病预防控制中心标准诊断为CFS的18-65岁男性或女性参与者;
2)近1个月内未接受过任何针对CFS的治疗
3)自愿提供签署的同意书。
根据CDC标准,CFS患者必须表现出以下症状:
a)连续6个月或更长时间持续或反复出现疲劳,这与持续劳累或其他与疲劳有关的医疗状况无关,
b)明显干扰个人活动的疲劳和工作
c)四个或更多并发症状(短期记忆或注意力集中受损;喉咙痛;颈或腋窝淋巴结压痛;肌肉疼痛;无关节肿胀或发红的多关节疼痛;新型头痛,或严重程度;不清醒的睡眠;以及运动后不适持续超过24小时)。

Inclusion criteria

1) Male or female participants aged 18-65 who were diagnosed with CFS according to CDC criteria;
2) Have not received any treatment for CFS in the past 1 month
3) Voluntarily provide signed consent forms.
According to CDC standards, CFS patients must show the following symptoms:
A) Persistent or recurrent fatigue for 6 months or more, not related to persistent fatigue or any other medical condition related to fatigue,
B) fatigue and work that significantly interferes with personal activities
C) Four or more concurrent symptoms (impaired short-term memory or concentration; Sore throat; Tenderness of cervical or axillary lymph nodes; Muscle pain; Multiple joint pain without joint swelling or redness; New headache, or severity; Unawake sleep; And discomfort lasting more than 24 hours after exercise).

排除标准:

1.不符合纳入标准者;
2.妊娠或哺乳期妇女;
3.病前2年至今有各种不良嗜好,嗜烟、酗酒等;
4.合并心、肝、肾、脑等脏器功能不全或精神病患者;
5.原发性或器质性疾病导致的慢性疲劳患者;
6.过度肥胖者(体质量指数≥45);
7.在试验前3个月内参加其他临床试验;
8.过敏体质或对中药已知成分过敏者。

Exclusion criteria:

1) Male or female participants aged 18-65 who were diagnosed with CFS according to CDC criteria;
2) Have not received any treatment for CFS in the past 1 month
3) Voluntarily provide signed consent forms.
According to CDC standards, CFS patients must show the following symptoms:
A) Persistent or recurrent fatigue for 6 months or more, not related to persistent fatigue or any other medical condition related to fatigue,
B) fatigue and work that significantly interferes with personal activities
C) Four or more concurrent symptoms (impaired short-term memory or concentration; Sore throat; Tenderness of cervical or axillary lymph nodes; Muscle pain; Multiple joint pain without joint swelling or redness; New headache, or severity; Unawake sleep; And discomfort lasting more than 24 hours after exercise).

研究实施时间:

Study execute time:

From 2022-01-17 00:00:00 To 2022-01-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-01-07 00:00:00 To 2022-01-15 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

40

Group:

The control group

Sample size:

干预措施:

健康教育

干预措施代码:

Intervention:

Health education

Intervention code:

组别:

试验组

样本量:

40

Group:

The experimental group

Sample size:

干预措施:

药食同源组方

干预措施代码:

Intervention:

Homologous medicine and food recipe

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河北 

市(区县):

石家庄 

Country:

China

Province:

Hebei

City:

Shijiazhuang

单位(医院):

河北医科大学第一医院 

单位级别:

三级甲等 

Institution
hospital:

the First Hospital of Hebei Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

一般情况调查表

指标类型:

主要指标

Outcome:

General information questionnaire

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

健康状况调查问卷(SF-36)

指标类型:

主要指标

Outcome:

The Short-Form (SF-36) Health Survey

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疲劳症状

指标类型:

主要指标

Outcome:

Symptoms of fatigue

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疲劳严重程度量表(FSS)

指标类型:

主要指标

Outcome:

Fatigue severity scale, FSS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

no

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

no

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-01-11 05:06:21